TABLE 3.
HPV genotyping prevalences according to the Onclarity and GP-LMNX assays, stratified by cytology result
| Assay and HPV genotype | No. (%) of samples with the following cytology resulta
: |
Prevalence (no. [%]) among all samples (n, 1,295 or 1,288)b
|
||||
|---|---|---|---|---|---|---|
| Normal (n, 947 or 940)b | ASCUS (n, 106) | LSIL (n, 121) | HSIL (n, 106) | AGC/ASC-H/AIS (n, 15) | ||
| Onclarity assay | ||||||
| All hrHPV types | 73 (7.7) | 103 (97.2) | 88 (72.7) | 93 (87.7) | 11 (73.3) | 368 (28.4) |
| HPV16 | 12 (1.3) | 26 (24.5) | 12 (9.9) | 36 (34.0) | 2 (13.3) | 88 (6.8) |
| HPV18 | 6 (0.6) | 7 (6.6) | 6 (5.0) | 10 (9.4) | 2 (13.3) | 31 (2.4) |
| HPV31 | 7 (0.7) | 13 (12.3) | 13 (10.7) | 16 (15.1) | 1 (6.7) | 50 (3.9) |
| HPV45 | 7 (0.7) | 13 (12.3) | 5 (4.1) | 8 (7.5) | 2 (13.3) | 35 (2.7) |
| HPV51 | 3 (0.3) | 7 (6.6) | 11 (9.1) | 8 (7.5) | 1 (6.7) | 30 (2.3) |
| HPV52 | 13 (1.4) | 12 (11.3) | 12 (9.9) | 11 (10.4) | 0 (0) | 48 (3.7) |
| HPV33/58 | 10 (1.1) | 13 (12.3) | 7 (5.8) | 14 (13.2) | 2 (13.3) | 46 (3.6) |
| HPV56/59/66 | 12 (1.3) | 20 (18.9) | 37 (30.6) | 10 (9.4) | 3 (20.0) | 82 (6.3) |
| HPV35/39/68 | 18 (1.9) | 19 (17.9) | 18 (14.9) | 5 (4.7) | 1 (6.7) | 61 (4.7) |
| GP-LMNX assay | ||||||
| All hrHPV types | 122 (13.0) | 97 (91.5) | 86 (71.1) | 97 (91.5) | 10 (66.7) | 412 (32.0) |
| HPV16 | 25 (2.7) | 26 (24.5) | 11 (9.1) | 38 (35.8) | 2 (13.3) | 102 (7.9) |
| HPV18 | 23 (2.4) | 8 (7.5) | 7 (5.8) | 10 (9.4) | 2 (13.3) | 50 (3.9) |
| HPV31 | 11 (1.2) | 12 (11.3) | 12 (9.9) | 16 (15.1) | 1 (6.7) | 52 (4.0) |
| HPV45 | 15 (1.6) | 14 (13.2) | 5 (4.1) | 7 (6.6) | 2 (13.3) | 43 (3.3) |
| HPV51 | 9 (1.0) | 8 (7.5) | 12 (9.9) | 8 (7.5) | 0 (0) | 37 (2.9) |
| HPV52 | 9 (1.0) | 9 (8.5) | 8 (6.6) | 6 (5.7) | 0 (0) | 32 (2.5) |
| HPV33/58c | 21 (2.2) | 13 (12.3) | 8 (6.6) | 13 (12.3) | 3 (20.0) | 58 (4.5) |
| HPV56/59/66c | 23 (2.4) | 22 (20.8) | 37 (30.6) | 13 (12.3) | 3 (20.0) | 98 (7.6) |
| HPV35/39/68c | 17 (1.8) | 15 (14.2) | 13 (10.7) | 3 (2.8) | 1 (6.7) | 49 (3.8) |
a
ASCUS, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesions; HSIL, high-grade squamous intraepithelial lesions; AGC, atypical glandular cells; ASC-H, atypical squamous cells for which HSIL cannot be excluded; AIS, adenocarcinoma in situ.
b
Seven samples were invalid with the GP-LMNX assay.
c
HPV genotypes have been pooled for comparison with the Onclarity assay. An HPV33-positive result, therefore, is counted in a combined HPV33/58 outcome. A multiple infection with, e.g., HPV33 and HPV58 is counted only once, as an HPV33/58 infection. The same applies to testing of HPV56/59/66 and HPV35/39/68.